Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (171-180 of 437) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2014
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)Tony Mok, Vera Gorbunova, Erzsebet Juhasz, et al.
Clinical Epigenetics|December 2, 2022
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patientsFlorian Janke, Arlou Kristina Angeles, Anja Lisa Riediger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
Pneumologie (Stuttgart, Germany)|October 14, 2025
[White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany]Torsten Gerriet Blum, Jens Vogel-Claussen, Hans Hoffmann, et al.
Journal of Geriatric Oncology|November 2, 2022
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON studyWolfgang M Brueckl, Martin Reck, Harald Schäfer, et al.
Nature Reviews. Disease Primers|January 8, 2025
Author Correction: Non-small-cell lung cancerLizza E L Hendriks, Jordi Remon, Corinne Faivre-Finn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyMartin Reck, Koichi Hagiwara, Baohui Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST studyClaus-Peter Schneider, David Heigener, Kathrin Schott-von-Römer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerMartin Reck, Luis G Paz-Ares, Filippo de Marinis, et al.
Nature Reviews. Disease Primers|September 26, 2024
Non-small-cell lung cancerLizza E L Hendriks, Jordi Remon, Corinne Faivre-Finn, et al.
Pageof 44

Showing results (171-180 of 437) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2014
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)Tony Mok, Vera Gorbunova, Erzsebet Juhasz, et al.
Clinical Epigenetics|December 2, 2022
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patientsFlorian Janke, Arlou Kristina Angeles, Anja Lisa Riediger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
Pneumologie (Stuttgart, Germany)|October 14, 2025
[White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany]Torsten Gerriet Blum, Jens Vogel-Claussen, Hans Hoffmann, et al.
Journal of Geriatric Oncology|November 2, 2022
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON studyWolfgang M Brueckl, Martin Reck, Harald Schäfer, et al.
Nature Reviews. Disease Primers|January 8, 2025
Author Correction: Non-small-cell lung cancerLizza E L Hendriks, Jordi Remon, Corinne Faivre-Finn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyMartin Reck, Koichi Hagiwara, Baohui Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST studyClaus-Peter Schneider, David Heigener, Kathrin Schott-von-Römer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerMartin Reck, Luis G Paz-Ares, Filippo de Marinis, et al.
Nature Reviews. Disease Primers|September 26, 2024
Non-small-cell lung cancerLizza E L Hendriks, Jordi Remon, Corinne Faivre-Finn, et al.
Pageof 44